Beth HoffmanFounder and CEO at Origami Therapeutics, Inc.
Beth J. Hoffman, Ph.D. Founder and Chief Executive Officer at Origami Therapeutics, Inc. At Origami, Dr. Hoffman is leveraging lessons learned during 20 years of CNS drug discovery to create a novel, precision medicine approach to treating neurodegenerative diseases by “fixing broken proteins”. This approach targets the underlying cause of disease using small molecules to modulate protein folding and conformation. Prior to Origami, Dr. Hoffman was the Vice President, Discovery Biology for Vertex Pharmaceuticals, Inc. where she guided the development of paradigm-shifting treatments for Cystic Fibrosis (Kalydeco, Orkambi, Symdeco, Trikafta). Prior to Vertex, she was a Research & Development executive at Amgen and Eli Lilly. A Fellow of the ACNP and past Laureate of the Anna Monica Stiftung, she has directed over 30 drug programs into the clinic. Dr. Hoffman serves as a Scientific Adviser to Arctoris and on the Board of Directors for the San Diego Chapter of the Huntington’s Disease Society of America (HDSA). Dr. Hoffman received an A.B. in Molecular Biology from Wellesley College, a Ph.D. in Cell Biology from the Johns Hopkins University and was Chief of the Molecular Pharmacology Unit at the National Institute of Mental Health, Bethesda, MD.